CN104302636B - C型肝炎病毒抑制剂 - Google Patents

C型肝炎病毒抑制剂 Download PDF

Info

Publication number
CN104302636B
CN104302636B CN201380022245.8A CN201380022245A CN104302636B CN 104302636 B CN104302636 B CN 104302636B CN 201380022245 A CN201380022245 A CN 201380022245A CN 104302636 B CN104302636 B CN 104302636B
Authority
CN
China
Prior art keywords
alkyl
methyl
compound
mmol
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380022245.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104302636A (zh
Inventor
罗伯特·默里·麦金内尔
丹尼尔·D·朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Theravance Biopharma R&D IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D IP LLC filed Critical Theravance Biopharma R&D IP LLC
Publication of CN104302636A publication Critical patent/CN104302636A/zh
Application granted granted Critical
Publication of CN104302636B publication Critical patent/CN104302636B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380022245.8A 2012-04-25 2013-04-24 C型肝炎病毒抑制剂 Expired - Fee Related CN104302636B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261637956P 2012-04-25 2012-04-25
US61/637,956 2012-04-25
US201361773977P 2013-03-07 2013-03-07
US61/773,977 2013-03-07
PCT/US2013/037934 WO2013163270A1 (en) 2012-04-25 2013-04-24 Hepatitis c virus inhibitors

Publications (2)

Publication Number Publication Date
CN104302636A CN104302636A (zh) 2015-01-21
CN104302636B true CN104302636B (zh) 2017-03-29

Family

ID=48227586

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380022245.8A Expired - Fee Related CN104302636B (zh) 2012-04-25 2013-04-24 C型肝炎病毒抑制剂

Country Status (7)

Country Link
US (2) US9066944B2 (https=)
EP (1) EP2850072B1 (https=)
JP (1) JP6069492B2 (https=)
CN (1) CN104302636B (https=)
CA (1) CA2869908C (https=)
ES (1) ES2599665T3 (https=)
WO (1) WO2013163270A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032173T2 (en) * 2012-04-25 2017-09-28 Theravance Biopharma R&D Ip Llc Piperazine piperidine compounds as inhibitors of hepatitis C virus
GB202013383D0 (en) * 2020-08-26 2020-10-07 Givaudan Sa Process

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094977A1 (en) * 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
WO2011091417A1 (en) * 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2012018325A1 (en) * 2010-08-04 2012-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2012021704A1 (en) * 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2012061552A1 (en) * 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
PT3309157T (pt) 2009-05-13 2019-12-02 Gilead Pharmasset Llc Compostos antivirais
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA201290882A1 (ru) 2010-03-09 2013-04-30 Мерк Шарп Энд Домэ Корп. Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
CN103946220B (zh) * 2011-11-03 2017-12-22 施万生物制药研发Ip有限责任公司 含有片段{2‑[4‑(联苯‑4‑基)‑1h‑咪唑‑2‑基]吡咯烷‑1‑羰基甲基}胺的杆状丙型肝炎病毒抑制剂
US8883135B2 (en) * 2012-05-03 2014-11-11 Theravance Biopharma R&D Ip, Llc Crystalline form of a pyridyl-piperazinyl hepatitis C virus inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094977A1 (en) * 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
WO2011091417A1 (en) * 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2012018325A1 (en) * 2010-08-04 2012-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2012021704A1 (en) * 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2012061552A1 (en) * 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus

Also Published As

Publication number Publication date
JP2015515494A (ja) 2015-05-28
JP6069492B2 (ja) 2017-02-01
US20150252023A1 (en) 2015-09-10
US20130287731A1 (en) 2013-10-31
US9365549B2 (en) 2016-06-14
EP2850072B1 (en) 2016-08-31
WO2013163270A1 (en) 2013-10-31
EP2850072A1 (en) 2015-03-25
US9066944B2 (en) 2015-06-30
CA2869908A1 (en) 2013-10-31
CN104302636A (zh) 2015-01-21
CA2869908C (en) 2018-02-20
ES2599665T3 (es) 2017-02-02

Similar Documents

Publication Publication Date Title
CN103946220B (zh) 含有片段{2‑[4‑(联苯‑4‑基)‑1h‑咪唑‑2‑基]吡咯烷‑1‑羰基甲基}胺的杆状丙型肝炎病毒抑制剂
CN103189371B (zh) 丙型肝炎病毒抑制剂
CN102378762B (zh) 丙型肝炎病毒抑制剂
CN102459250B (zh) 丙型肝炎病毒抑制剂
JP5612612B2 (ja) Ｃ型肝炎ウイルス阻害剤
JP2014148550A (ja) 抗ウイルス化合物
TWI585082B (zh) 作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們的用途
CN101754966A (zh) 丙型肝炎病毒抑制剂
TW201439060A (zh) 作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途
CN104302636B (zh) C型肝炎病毒抑制剂
CN104302639B (zh) 作为c型肝炎病毒抑制剂的哌嗪‑哌啶化合物
NZ623846B2 (en) Rod-like hepatitis c virus inhibitors containing the fragment {2-[4-(bi phenyl-4-yl) -1h-imidazo-2-yl] pyrrolidine-1-carbonlymethyl} amine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170329

Termination date: 20180424